Read, Watch or Listen

The FDA announced it will restrict Covid-19 vaccine access to those 65+ and high-risk individuals. This decision, detailed in a New England Journal of Medicine commentary by FDA Commissioner Marty Makary and Dr. Vinay Prasad, reflects a shift away from universal vaccination. The agency will require manufacturers to conduct clinical trials proving the vaccines' benefit for younger, healthy populations. This change aligns the US approach more closely with global practices, considering the widespread immunity developed through prior infections and vaccinations.

Prepared by Olivia Bennett and reviewed by editorial team.